Drugs / MACOZINONE
MACOZINONE
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT03776500 | Feb 2019 → Mar 2020 | pulmonary tuberculosis | Innovative Medicines for Tuberculosis | Completed | No outcome recorded |
| Phase 1 | NCT04150224 | Jul → Nov 2018 | — | Nearmedic Plus LLC | Completed | No outcome recorded |
| Phase 1 | NCT03423030 | Dec 2017 → Mar 2018 | pulmonary tuberculosis | Innovative Medicines for Tuberculosis | Completed | No outcome recorded |
| Phase 1 | NCT03036163 | Jan → Sep 2016 | tuberculosis | Nearmedic Plus LLC | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03334734 | Dec 2016 → Sep 2017 | tuberculosis | Nearmedic Plus LLC | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MACOZINONE | ChEMBL registry synonym — accepted as the source's own label CHEMBL3330226 ↗ |
| Known as | Macozinona | ChEMBL registry synonym — accepted as the source's own label CHEMBL3330226 ↗ |
| Known as | Macozinone (PBTZ169) | “Macozinone (PBTZ169)” NCT04150224 ↗ |
| Known as | PBTZ169 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04150224 ↗ |
| Modality | Small molecule | — CHEMBL3330226 ↗ |
| Route | Oral | “40 mg of PBTZ169 (1 capsule) orally once in fasting state” NCT03036163 ↗ |